Literature DB >> 3126183

Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties.

N K Kalyan1, S G Lee, J Wilhelm, K P Fu, W T Hum, R Rappaport, R W Hartzell, C Urbano, P P Hung.   

Abstract

Tissue-type plasminogen activator (t-PA) is a mosaic protein containing several distinct structural domains attached to the serine protease catalytic unit present at its COOH terminus. To investigate structure-function relationships in t-PA, we deleted the NH2-terminal domains, finger and epidermal growth factor, by genetic engineering. The genes for the parent and mutant t-PA were expressed in a bovine papilloma virus-dependent mammalian cell system. The secreted proteins were purified to homogeneity. The mutant protein was processed to the expected size of about 60 kDa compared to approximately 68 kDa for the parent t-PA, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and fibrin autography. While the mutant t-PA had amidolytic activity comparable to native t-PA, it did not bind appreciably to fibrin. Consequently, fibrin-dependent enzymic activity, i.e. plasminogen activation in the presence of soluble fibrin and fibrinolysis were lower than with native recombinant t-PA. The effect of deletion of NH2-terminal domains on the plasma half-life (t1/2) was investigated by injecting native and mutant t-PA into mice. While the majority of the t-PA disappeared initially with a t1/2 of about 2 min, mutant t-PA cleared at a much slower rate with t1/2 of about 50 min. These findings suggest that the NH2-terminal domains of t-PA not only determine its specificity for binding to fibrin but also mediate its clearance from plasma in vivo. Furthermore, the catalytic unit in t-PA seems to function autonomously.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3126183

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator.

Authors:  G L Reed; A K Houng; L Liu; B Parhami-Seren; L H Matsueda; S Wang; L Hedstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 2.  Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Authors:  R Fears
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

3.  High-level expression of a novel recombinant human plasminogen activator (rhPA) in the milk of transgenic rabbits and its thrombolytic bioactivity in vitro.

Authors:  Shaozheng Song; Xin Ge; Yaobin Cheng; Rui Lu; Ting Zhang; Baoli Yu; Xueqiao Ji; Zhengqiang Qi; Yao Rong; Yuguo Yuan; Yong Cheng
Journal:  Mol Biol Rep       Date:  2016-05-26       Impact factor: 2.316

Review 4.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 5.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10

6.  Random PCR mutagenesis screening of secreted proteins by direct expression in mammalian cells.

Authors:  G C Rice; D V Goeddel; G Cachianes; J Woronicz; E Y Chen; S R Williams; D W Leung
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

7.  alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.

Authors:  K A Hajjar; C M Reynolds
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

8.  Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.

Authors:  J Kuiper; A Van't Hof; M Otter; E A Biessen; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

9.  Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain.

Authors:  M J Gething; B Adler; J A Boose; R D Gerard; E L Madison; D McGookey; R S Meidell; L M Roman; J Sambrook
Journal:  EMBO J       Date:  1988-09       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.